HomeNews

News

  • First Phase I candidate recruited for Jülich’s Alzheimer’s therapy

    • April 19, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Biogen’s BIIB054 displays positive Phase I results in Parkinson’s

    • April 19, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Shire Announces Sale of Oncology Business to Servier for $2.4 Billion to Focus on Rare Disease Leadership

    • April 18, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Teva to Present New Data Across Multiple NS Therapeutic Areas at AAN

    • April 18, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • National MS Society commits $14.2 Million to new MS research

    • April 18, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Aimovig halves Migraine days in difficult to treat patients, study to be presented an AAN finds

    • April 18, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • GW cannabis-derived epilepsy drug gets positive FDA staff review

    • April 17, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • SPMS patients have higher cognitive decline than RRMS patients, study reports

    • April 17, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Long term Dementia risks associated with Brain injury, new study finds

    • April 17, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Genentech to Present New Data for Ocrevus and NS pipeline expansion at AAN

    • April 16, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more